SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

12 Aug 2025 Evaluate

Pfizer has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant advancement in protection against pneumococcal disease in adults. Pfizer’s vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease.

It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single shot vaccine and those vaccinated with PCV20 may not need a second dose. Adults over 50 years of age, as well as individuals with comorbidities such as asthma, COPD (Chronic Obstructive Pulmonary Disease), chronic kidney disease, and diabetes, face a higher risk of developing pneumococcal infections, which can result in complications, hospitalization, and even death.

Timely immunization is critical to reducing the risk of severe illness, hospitalization, and mortality caused by pneumococcal disease. Vaccination with PCVs are considered one of the most effective public health tools for reducing the burden of pneumococcal disease. The introduction of PCV20 in India strengthens Pfizer’s longstanding commitment to preventive health and builds on 25 years of leadership in pneumococcal vaccine innovation.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.


Pfizer Share Price

4811.05 61.45 (1.29%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×